Business:
Allogeneic cellular immunotherapy platform
Drug notes:
Also Clin0 multiple cancers; NKX019 Clin1 B cell malignancies; undisclosed RD oncology; undisclosed RD undisclosed
About:
Nkarta Therapeutics is advancing the development of natural killer (NK) cell therapies. NK cells are the immune system’s first responders against diseases and pathogens, with an inherent ability to target tumor cells. Nkarta is using their proprietary technology to harness the power of NK cells and enhance their ability to search and destroy tumor cells. This involves redesigning NK cells to maximize their therapeutic effect through robust expansion, enhanced targeting and extended persistence to create a sustained anti-cancer immune-mediated attack. Nkarta’s goal is to offer a versatile and robust approach to cancer therapy to improve patient outcomes.